Member Info for Thompi

Morning BV, I found a copy of the TG notes, and yes, it was Fiona who answered a question about weekly dosing:

“Now that we have seen how safe AVA6000 is we know we could do more frequent dosing. It’s important to remember we are not dosing Dox but AVA6000 which is a targeted version of DOX and dosing every two weeks may give better outcomes for patients. Weekly dosing could increase toxicity and fatigue, so it may be considered in the future but we have decided to trial fortnightly dosing.” (18th October 2023)

https://x.com/sarahjean191/status/1717536397416869977?s=61&t=yGNoQ6Xj0Lw6rjPJMTuiZA

( I am not Sarah Stevens, I just remember her posting the notes)

BSHS2L, this is a clinical trial with clearly defined parameters agreed by the Safety Data Monitoring Committee. I think it unlikely that a patient could move from one dosing regimen to another, especially as the fortnightly trial is in its very early stages? But that is supposition on my part and not fact.

Interesting suggestion, but I am surmising it is probably not possible?

TG2D, you are talking cr*p. Angle, itself, is using Parsortix for studies in ovarian & prostate cancer and plan to offer LDT’s for them. Two of AGL’s customer’s are using Parsortix in non MBC trials. There are countless independent studies using Parsortix for a whole host of different cancer types. AN has explained, on a number of occasions, how CLIA accredited labs can use Parsortix for different cancers. And yet, you still persist talking rubbish.

If your motive is to annoy people, well congratulations it’s working with me. I don’t like filtering people, because I like to hear different views, but I am going to make an exception with you. You’re binned.

I will be paying more attention than usual to the Diagnostic division in the upcoming prelims. In the TP note it said “Avacta’s Board expects the Diagnostics division to become EBITDA positive in 2H 2024 and cash generative in 2025.”

Shareholders don’t want it indefinitely losing money and the for sale sign is up, so we obviously want the best return when it’s flogged. It’s going to be very interesting to see what DX eventually sells/is divested for.

Agreed PL, has the DX side contributed/developed anything marketable since the LFT’s?

I invested because of the potential of the Therapeutics division and have never had much interest in the Diagnostics. I re-listened to what AS said in the interims about it, it wasn’t very compelling, and is even less so now.

Hi Noix again. I wasn’t invested at the time of the last presentation and watched it “retrospectively”. From memory, I think there were about four questions asked. If there were others that were not later addressed, then that is poor.

Morning Noix, it was the same with last year’s results - the Investor Meet presentation was with both the CEO & CFO.

To the people who routinely report/censor posts, please will you take into consideration that LSE will also wipe out a whole load of other post as well. It makes trying to catch up on the day’s posts very disjointed and interesting posts get deleted. There is also not much point in taking time to write a post if it’s just going to be indiscriminately removed.

There has been criticism of the Telegram group but this board is more controlling of content. Much better to use the poster filter on here rather than having a whole “conversation” deleted.

Thanks CTSFO for posting the TD research note.

https://www.trinitydelta.org/research-notes/aacr-data-continue-to-support-confidence-in-ava6000/

Wyn, there is a good opportunity to ask the type of questions you are raising at the upcoming webinar on the 10th April. I hope you do ask, I would be genuinely interested in the reply.

Wyn, I disagree with your comment: “I also think that if the data was as compelling as we all have been told, getting patients for the trial would have taken, oh, |I don't know about 5 minutes?” The “5 minutes” patient enrollment reference may have been meant flippantly but it disrespectful to the patient’s who are very ill, and to quote Andrew Saunders are “very much doing an altruistic act in entering these trials…..”.

AS’s missed timelines may be frustrating if they are unrealistic, but these are people’s lives we are talking about, the screening process cannot be compromised for the sake of shareholders. The company and the oncologists also need to be selective in their choice of patients in order to get the optimum results for the trial.

The trouble with the self appointed censors of the board getting posts deleted is that other posts also get swept up.

So I will repost mine to Touk.

The word “exceeded” is used twice by AS in the PH VOX interview 13th December 2023.

“I think it's fair to say that what we have now has EXCEEDED all expectations and that the overarching takeaway message from the data we released this morning is that Pre|CISION is doing exactly what it was intended to ……….we're in a position where we can see now that we can improve the quality of life of patients and that was probably, pragmatically our aim when we started the safety study. But as I say, we've far EXCEEDED that now…..”

The first mention is approximately 3:13 into the interview.

https://www.voxmarkets.co.uk/articles/q-a-with-avacta-s-ceo-alastair-smith-790c4e8/

Moniman, we are both invested in Hvivo, but why have showed up on this board?

Hvivo has had its ups & downs (although doing very well now), how would you like it if someone turned up trolling that board when they are not invested. It’s disrespectful to investors and is basically just having a 💩stir. Perhaps you are bored but please don’t come on here because it is not appreciated.

TG2D “Your getting confused between 'Research ' use of Parsortix and actual 'Testing' of patients to determine cancer type and appropriate drug remedy to be used during treatment….”

I don’t agree. Parsortix is being used in important trials to help identify or “test” new treatments in various clinical trials.

The Solaris prostate collaboration study “is designed to assess the ability to detect prostate cancer and assess its severity”.

“Successful development of this simple blood test could prevent men from being subjected to unnecessary tissue biopsies when they either do not have prostate cancer (despite the elevated level of PSA) or their cancer is indolent and unlikely to impact either their life expectancy or quality of life.” (AN Solaris collaboration RNS)

Angle themselves are intending to eventually offer tests - “Angle is putting a lot of effort into our clinical laboratory. So, that we were aiming at, by the end of the year, we'll be able to offer tests for patients, not just about patients, but for patients.” (Proactive presentation 2023).

The reason I copy and paste is to back up and show the source of my information. But your approach is why let the truth get in the way of a good troll, you take some misinformation and spin it for all it’s worth.

TG2D you are talking rubbish. There is a wealth of independent research validating Parsortix in numerous different cancers.

To repeat - as Miavoce said, and as you are well know, CLIA approved labs are allowed to use Parsortix to perform laboratory developed tests on ALL cancer types. There is need for FDA approval. It has been explained numerous times to you on here & ADVFN.

The reason that research is copied and pasted on this board is to demonstrate the various clinical trials that are using Parsortix for MULTIPLE cancer types.

Are you suggesting that AGL cancel their prostate collaboration with Solaris? Or that Barts terminate their prostate clinical trial using Parsortix? Or that the Centre Hospitalier Universitaire de Nīmes Proof-of-Concept Study “to investigate the intestinal polyp secretion of tumour cells and circulating factors” is invalid? Or that Crecsendo Biological & Artios Pharma cancel their contracts……..

TG2D the Shares/Proactive presentations had a very tight time slot including the Q&A and were geared towards new investors. Hence the schematic of how Parsortix works etc. Given the time constraints AN covered a lot. If you want more detail contact the company or watch the results presentation.

As Miavoce said, and as you are well know, CLIA approved labs are allowed to use Parsortix to perform laboratory developed tests on ALL cancer types. There is need for FDA approval. It has been explained numerous times to you on here & ADVFN. Have you got nothing better to do than maliciously troll a board you are not invested in? I am contemptuous of you. At least you have moved on from trying to compare Parsortix to Theranos. That was ridiculous, even by your standards.

Moab, Parsortix is not a “one trick pony”. It’s FDA approval may be for MBC but there is a ton of independent research using Parsortix for a whole host of different cancer types.

Two of AGL’s customers are using Parsortix in clinical trials that are not related to, or exclusively related to MBC:

Artios Pharma

Cancer treatments targeting DNA Damage Response (DDR) pathways

• Bespoke assay development of DDR assay to measure DNA damage on CTCs

• Phase I study in advanced solid tumours (Breast, Ovarian, Prostate).

Crescendo Biologics

Immuno-oncology company developing targeted T cell enhancing therapeutics

* Portrait Flex assay to detect and phenotype CTCs and clusters

* Phase I prostate

Then there is AGL’s collaboration with Solaris Health in prostate cancer. And the Prostate UK sponsored research (Barts Cancer Institute) using Parsortix etc, etc

With the BiDetect, using Illumina’s NGS platform, AGL used a pan cancer panel for DNA mutations. It is up to AGL’s Pharma Services customer’s discretion which cancer types they analyse.

I agree Watching, it’s a great RNS. Key thing for me is the news that Q2W has started dosing. But the comms have definitely got to improve - for example, the only way we knew that the company would notify the market on dosing the third patient was via private emails. That’s not good enough.

Were you happy with the circumstance of the 50p placing, especially after being told there was optionality and not to worry about funding?

Ps, I’m looking forward to the AACR and more detail on this comment:“AVA6000 is already showing encouraging preliminary clinical signs of anti-tumor activity”. I think there is a lot of good news to come.

PH has come in for some criticism for his “bumble’ism” but he is on Twitter & LinkedIn today promoting the cause.

https://www.linkedin.com/posts/paul-hill-a5994116_avct-avct-activity-7176495805606854658-YSS_?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy

Thorn, the only part of your earlier post that I agree with, is when you ask the question “Could the raise have not come after this RNS?”

Surely, if the company’s comms had been better we could have had a placing higher than 50p? Very positive RNS but I still think AS & EF should forgo some of their options after presiding over such a shocker of a fund raise.